Drug intelligence / Profile preview

KB305

Development stage: Preclinical
Lead developer: Jeune Aesthetics
Modality: Recombinant Proteins and Enzymes, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
Administration: Intranasal

Overview

**KB305** is a preclinical gene therapy candidate developed by Krystal Biotech for aesthetic skin conditions. It involves gene transference to deliver **type IV collagen**, a key extracellular matrix protein, aiming to replenish and restore skin structure for rejuvenation. Initially developed by Krystal Biotech, its global highest R&D status is preclinical, with potential applications in collagen replacement therapies for dermatological aesthetics.[7][9]

Targets

MYH9 (Non-muscle myosin IIA)COL4 (Collagen IV)

Beyond the preview

Go deeper on KB305.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KB305.

Explore the full profile